Who owns Janux Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of JANX from SEC Form 13F filings across 204 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 204 institutions disclosed 61.3M shares of Janux Therapeutics, Inc. worth $1.06B — about 97.2% of shares outstanding; the largest disclosed holder is RA CAPITAL MANAGEMENT, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
204
13F holders
$1.06B
value, 2026 filers
97.2%
of shares outstanding (61.3M sh)
35
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of JANX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 11.2M | $193.4M | 1.9% | 17.7% | 0.0% |
| 2 | BlackRock, Inc. | 6.5M | $112.9M | 0.0% | 10.4% | +6.5% |
| 3 | Prosight Management, LP | 2.9M | $50.9M | 9.9% | 4.7% | -22.6% |
| 4 | FEDERATED HERMES, INC. | 2.6M | $44.8M | 0.1% | 4.1% | +10.3% |
| 5 | FMR LLC | 2.5M | $43.4M | 0.0% | 4% | +4.0% |
| 6 | STATE STREET CORP | 2.3M | $39.9M | 0.0% | 3.7% | -23.1% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $37.2M | 0.0% | 3.4% | +15.9% |
| 8 | TWO SIGMA INVESTMENTS, LP | 1.8M | $31.9M | 0.0% | 2.9% | +52.9% |
| 9 | TCG Crossover Management, LLC | 1.8M | $30.9M | 0.9% | 2.8% | 0.0% |
| 10 | Point72 Asset Management, L.P. | 1.6M | $27.3M | 0.0% | 2.5% | -20.8% |
| 11 | D. E. Shaw & Co., Inc. | 1.5M | $26.1M | 0.0% | 2.4% | +37.7% |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.5M | $25.1M | 0.0% | 2.3% | +9.2% |
| 13 | ALGERT GLOBAL LLC | 1.4M | $24.6M | 0.3% | 2.3% | +28.0% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1.3M | $22.1M | 0.0% | 2% | +6.4% |
| 15 | Alyeska Investment Group, L.P. | 1.1M | $18.9M | 0.0% | 1.7% | -33.5% |
| 16 | Nuveen, LLC | 1.0M | $18.1M | 0.0% | 1.7% | +975.8% |
| 17 | GOLDMAN SACHS GROUP INC | 1.0M | $17.7M | 0.0% | 1.6% | +7.8% |
| 18 | MORGAN STANLEY | 961,587 | $16.6M | 0.0% | 1.5% | +14.9% |
| 19 | WELLINGTON MANAGEMENT GROUP LLP | 920,679 | $15.9M | 0.0% | 1.5% | -38.9% |
| 20 | Nantahala Capital Management, LLC | 857,334 | $14.8M | 0.5% | 1.4% | +5.9% |
| 21 | ADAR1 Capital Management, LLC | 823,876 | $14.2M | 0.6% | 1.3% | +95.8% |
| 22 | AMERIPRISE FINANCIAL INCNEW | 749,137 | $12.9M | 0.0% | 1.2% | new |
| 23 | Qube Research & Technologies Ltd | 647,261 | $11.2M | 0.0% | 1% | -7.8% |
| 24 | ORBIMED ADVISORS LLC | 524,700 | $9.1M | 0.2% | 0.8% | 0.0% |
| 25 | BANK OF AMERICA CORP /DE/ | 506,368 | $8.8M | 0.0% | 0.8% | -44.4% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.